Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder

Next Previous
X
Search
Trial Profile

Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LU AA34893 (Primary) ; Quetiapine
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Jul 2022 This trial has been completed in Germany (End Date: 19 Jun 2008), according to the European Clinical Trials Database record.
    • 05 Oct 2021 This trial has been completed in France (Global end date: 19 June 2008).
    • 03 Jul 2012 Actual initiation date (28 Nov 2007) added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top